Replies to post #219224 on Avid Bioservices Inc (CDMO)

[vanessapu]

I have a dumb question could someone stolen Bavi and made a minor change

[Protector]

north4K, I don't know. The first one is only 5 months old and the last one is even more straight forward then all others.

But OK, I could understand that a company like BI has some form of platform to inform the public on several topics. But what caught my attention, and for which I have no explanation and not even a rational approach to even begin to explain it, is that they ADVERTISE these 2nd ln NSCLC movies.

As said, I found it as an ad (thank cj's for add->ad) on my IHub screen. Why would they advertise (pay) for that message. Furthermore I was under the impression that with Opdivo doing better then Docetaxel alone in non-squamous 2nd ln NSCLC, as was recently CLAIMED, by BMY with an early stopped clinical trial, this message would be quite misplaced or either erroneous.

That is of course unless we are all going to be disappointed by the BMY clinical trial details that could have been over-hyped.

I can possibly speculate about this 25 more pages but I think I'll get NO WHERE with this one.

[exwannabe]

Re: Boehringer

Another explanation is that BI actually does have a NSCLC agent on the market, afatanib.

Also, the PS!!! link was referring to Patient Status, very clear.